[go: up one dir, main page]

UY26529A1 - Composición de gliburida. - Google Patents

Composición de gliburida.

Info

Publication number
UY26529A1
UY26529A1 UY26529A UY26529A UY26529A1 UY 26529 A1 UY26529 A1 UY 26529A1 UY 26529 A UY26529 A UY 26529A UY 26529 A UY26529 A UY 26529A UY 26529 A1 UY26529 A1 UY 26529A1
Authority
UY
Uruguay
Prior art keywords
gliburide
composition
glyburide
physical form
methoxybenzamide
Prior art date
Application number
UY26529A
Other languages
English (en)
Inventor
Gillian Cave
Sarah J Nicholson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26529A1 publication Critical patent/UY26529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una forma física del fármaco conocido como gliburida, también conocido como glibenclamida, y definido químicamente como 5-cloro-N-2-4- (ciclohexilamino)-carbonil¨amino sulfonil fenil etil -2-metoxibenzamida (Merck Index, Décima Edición, P. 642), así como a formas de dosificación, por ejemplo, tabletas y cápsulas, que incorporan esa forma física de la gliburida.
UY26529A 2000-01-14 2001-01-11 Composición de gliburida. UY26529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14

Publications (1)

Publication Number Publication Date
UY26529A1 true UY26529A1 (es) 2001-08-27

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26529A UY26529A1 (es) 2000-01-14 2001-01-11 Composición de gliburida.

Country Status (37)

Country Link
US (2) US20010036479A1 (es)
EP (1) EP1250321B1 (es)
JP (1) JP4787446B2 (es)
KR (1) KR100739906B1 (es)
CN (1) CN1210258C (es)
AR (1) AR031547A1 (es)
AT (1) ATE330937T1 (es)
AU (1) AU771705B2 (es)
BG (1) BG65782B1 (es)
BR (1) BR0107564A (es)
CA (1) CA2397294C (es)
CY (1) CY1106328T1 (es)
CZ (1) CZ20022429A3 (es)
DE (1) DE60120916T2 (es)
DK (1) DK1250321T3 (es)
EE (1) EE05020B1 (es)
ES (1) ES2264967T3 (es)
GE (1) GEP20043299B (es)
HU (1) HU228825B1 (es)
IL (2) IL150383A0 (es)
LT (1) LT5024B (es)
LV (1) LV12914B (es)
MX (1) MXPA02006835A (es)
MY (1) MY128577A (es)
NO (1) NO328152B1 (es)
NZ (1) NZ519920A (es)
PT (1) PT1250321E (es)
RO (1) RO121381B1 (es)
RU (1) RU2244707C2 (es)
SK (1) SK286925B6 (es)
TN (1) TNSN01005A1 (es)
TR (1) TR200201798T2 (es)
TW (1) TWI287989B (es)
UA (1) UA73968C2 (es)
UY (1) UY26529A1 (es)
WO (1) WO2001051463A1 (es)
ZA (1) ZA200205528B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
IL164154A0 (en) * 2002-03-21 2005-12-18 Teva Pharma Fine particle size pioglitazone
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
PL1677792T3 (pl) 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
JP2007534704A (ja) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 経口徐放性錠剤組成物およびその製造方法
RU2359677C2 (ru) * 2004-04-29 2009-06-27 Лотус Фармасьютикал Ко., Лтд Оральные таблетки с модифицированным высвобождением и способ их получения
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
WO2007131930A1 (en) * 2006-05-13 2007-11-22 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8883852B2 (en) 2008-10-22 2014-11-11 University of Pittburgh—Of the Commonwealth System of Higher Education Radioprotective agents
WO2010092126A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
JP7182605B2 (ja) 2017-04-10 2022-12-02 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド ｌｙｎキナーゼ活性化因子及びＴＲＰＭ８アゴニストを含む組成物及び医薬の製造におけるそれらの使用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
AR125033A1 (es) 2021-03-04 2023-05-31 Biogen Chesapeake Llc Formulación y métodos de gliburida de baja absorción
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
ATE137962T1 (de) * 1991-12-05 1996-06-15 Alfatec Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
NZ501260A (en) 1997-06-18 2002-09-27 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JP2001520984A (ja) * 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 水難溶性薬剤の固態溶剤及び固体分散体
ES2206868T3 (es) 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
MXPA02006835A (es) 2003-01-28
HUP0203852A2 (hu) 2003-04-28
ES2264967T3 (es) 2007-02-01
IL150383A (en) 2007-03-08
JP4787446B2 (ja) 2011-10-05
NO328152B1 (no) 2009-12-21
TNSN01005A1 (en) 2005-11-10
BG106870A (en) 2003-03-31
DK1250321T3 (da) 2006-07-31
DE60120916D1 (de) 2006-08-03
TR200201798T2 (tr) 2002-11-21
AR031547A1 (es) 2003-09-24
BR0107564A (pt) 2002-10-01
US20030185880A1 (en) 2003-10-02
EP1250321B1 (en) 2006-06-21
CA2397294C (en) 2011-03-22
WO2001051463A1 (en) 2001-07-19
RU2244707C2 (ru) 2005-01-20
CN1210258C (zh) 2005-07-13
RO121381B1 (ro) 2007-04-30
ZA200205528B (en) 2003-10-10
LT2002085A (en) 2003-01-27
CY1106328T1 (el) 2011-10-12
CA2397294A1 (en) 2001-07-19
PL356210A1 (en) 2004-06-14
UA73968C2 (en) 2005-10-17
BG65782B1 (bg) 2009-11-30
KR100739906B1 (ko) 2007-07-16
CZ20022429A3 (cs) 2003-06-18
AU771705B2 (en) 2004-04-01
NO20023367D0 (no) 2002-07-12
SK286925B6 (sk) 2009-07-06
RU2002121626A (ru) 2004-01-10
TWI287989B (en) 2007-10-11
EP1250321A1 (en) 2002-10-23
AU2474001A (en) 2001-07-24
NO20023367L (no) 2002-09-04
JP2003519681A (ja) 2003-06-24
US6830760B2 (en) 2004-12-14
KR20020073169A (ko) 2002-09-19
NZ519920A (en) 2004-06-25
US20010036479A1 (en) 2001-11-01
SK9832002A3 (en) 2003-07-01
HUP0203852A3 (en) 2005-05-30
LT5024B (lt) 2003-06-25
MY128577A (en) 2007-02-28
IL150383A0 (en) 2002-12-01
HU228825B1 (en) 2013-05-28
LV12914B (en) 2003-01-20
CN1395560A (zh) 2003-02-05
EE200200393A (et) 2003-10-15
EE05020B1 (et) 2008-06-16
PT1250321E (pt) 2006-09-29
ATE330937T1 (de) 2006-07-15
GEP20043299B (en) 2004-03-10
DE60120916T2 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
UY26529A1 (es) Composición de gliburida.
BR0207726A (pt) Sais farmacêuticos
BR0206627A (pt) Formulação farmacêutica
AR025426A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para lapreparacion de medicamentos y formas de administracion que contienen esas sales
BR0013826A (pt) Formas orais de apresentação
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
GT200200247A (es) Formulaciones farmaceuticas de 5,7,14-triazatetra-ciclo[10.3.0 2,11.0 4,9]-hexadeca-2(11),3,5,7,9-pentaeno
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
GT199900203A (es) Composiciones de celecoxib.
BR0012869A (pt) Forma de dosagem farmacêutica de componentes múltiplos
GT200400087A (es) Agentes para combatir parasitos en animales.
TW200716206A (en) Unitary pharmaceutical dosage form
ES2178896T3 (es) Nueva forma de sal de pantoprazol.
AR109263A2 (es) Composición que comprende moxidectina
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
UY27727A1 (es) Nueva composicion farmacéutica-
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
BRPI0620229A8 (pt) formulação

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20130711